Sunday 18 October 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.58
0.32
−8.21%
Follow RZLT
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
9.68 | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 | 1.45 | 0.32 | 2.78 |
Net Debt/EBITDA |
1.26 | 2.04 | 1.73 | 1.78 | 3.63 | 1.19 | 0.48 | 0.49 | 0.06 | 0.23 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 32.78% | 1.50% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 0.93 | 0.84 | 0.86 | 0.96 | 0.98 | 1.19 | 0.47 | 0.47 | 0.56 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 0.11 | 0.98 | (0.37) |
Interest Coverage |
— | — | — | (13.31) | (23.16) | (61.05) | (109.15) | (5.23) | (41.70) | (12,702.56) |
| (59.04%) | (52.56%) | (57.73%) | (38.99%) | (46.77%) | (124.92%) | (446.05%) | 2,962.34% | (1,307.73%) | (273.79%) | |
| (53.82%) | (48.28%) | (53.39%) | (37.51%) | (42.11%) | (78.03%) | (175.16%) | (443.50%) | (454.80%) | (219.99%) | |
ROIC |
0.00% | 0.00% | 0.00% | (245.12%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (314.30%) |
Return on Tangible Assets |
(78.26%) | (46.71%) | (57.46%) | (51.87%) | (27.44%) | (52.18%) | (277.58%) | (858.99%) | 771.23% | (279.20%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.62) | (0.91) | (1.11) | (0.87) | (2.18) | (2.66) | (4.20) | (424.59) | (11.29) | (16.61) |
Cash per Share |
1.04 | 2.21 | 2.47 | 1.99 | 8.27 | 5.35 | 1.73 | 326.00 | 1.48 | 5.43 |
Shareholders Equity per Share |
0.97 | 2.13 | 2.35 | 2.27 | 8.21 | 3.40 | 1.28 | 49.35 | (3.56) | 10.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.97 | 2.13 | 2.35 | 2.27 | 8.21 | 3.40 | 1.28 | 49.35 | (3.56) | 10.33 |
Free Cash Flow |
(64.63) | (69.07) | (57.37) | (44.63) | (39.62) | (20.44) | (24.17) | (15.07) | (12.57) | (13.72) |
Working Capital |
99.09 | 159.23 | 119.05 | 99.71 | 149.64 | 40.03 | 7.29 | 3.77 | (4.24) | 3.16 |
Capital Expenditures |
— | — | — | (0.15) | — | — | — | 0.23 | 1.54 | (0.41) |
Net Current Asset Value |
98.35 | 157.78 | 116.92 | 97.36 | 149.16 | 25.48 | 6.92 | 1.64 | (4.46) | 2.83 |
| Other line items | ||||||||||
Quick Ratio |
9.44 | 14.09 | 13.21 | 19.60 | 61.09 | 20.86 | 3.09 | 1.38 | 0.26 | 2.53 |
Depreciation/Fixed assets |
(58.98) | (32.82) | (27.19) | (9.64) | 27.31 | 3.41 | 0.55 | 47.77 | 4.27 | 0.21 |
Cash ROIC |
(31.00%) | (20.93%) | (23.14%) | (20.47%) | (13.21%) | (25.20%) | (138.22%) | (113.12%) | 542.94% | (105.42%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.62) | (0.91) | (1.11) | (0.87) | (2.18) | (2.66) | (4.20) | (431.10) | (12.68) | (16.12) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.51 | 1.39 | (0.49) |
Average Payables |
5.42 | 5.36 | 4.09 | 2.20 | 1.08 | 0.96 | 1.12 | 1.60 | 1.40 | 1.23 |
Average Assets |
144.17 | 154.11 | 128.23 | 138.07 | 97.51 | 26.79 | 11.61 | 7.38 | 6.57 | 10.77 |
Average Common Equity |
131.41 | 141.57 | 118.59 | 132.82 | 87.79 | 16.73 | 4.56 | (1.10) | 2.28 | 8.65 |
Capex to Sales |
— | — | — | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026